---
title: "Vaccinex says neoadjuvant melanoma pilot study links pepinemab regimens to immune remodeling, longer recurrence-free survival"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301144938.md"
description: "Vaccinex announced that a pilot neoadjuvant melanoma study, published in Nature Communications, links pepinemab regimens to immune remodeling and longer recurrence-free survival. The findings indicate that pepinemab combinations reshape the tumor immune environment, with more mature immune structures correlating with improved outcomes. While the small study does not prove benefit, data support pairing SEMA4D blockade with checkpoint inhibitors, necessitating larger randomized trials for confirmation."
datetime: "2026-10-07T12:32:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301144938.md)
  - [en](https://longbridge.com/en/news/301144938.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301144938.md)
generator: "portal-rs"
---

# Vaccinex says neoadjuvant melanoma pilot study links pepinemab regimens to immune remodeling, longer recurrence-free survival

-   Vaccinex announced a Nature Communications publication of results from an Emory-sponsored pilot neoadjuvant melanoma study of pepinemab. \* Findings were already presented via publication, not flagged for a future conference release. \* Pepinemab combinations reshaped the tumor immune environment in ways consistent with stronger anti-tumor immune activity. \* More mature immune structures in tumors correlated with longer recurrence-free survival, though the small study was not designed to prove benefit. \* Data support the strategy of pairing SEMA4D blockade with checkpoint inhibitors, with larger randomized trials needed for confirmation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaccinex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9840869) on October 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VCNX.US](https://longbridge.com/en/quote/VCNX.US.md)

## Related News & Research

- [Live Nation Entertainment (LYV) Expands Venues As Investors Weigh Its Valuation](https://longbridge.com/en/news/305560320.md)
- [How Shelf Registration Will Impact Celldex Therapeutics (CLDX) Stock Investors](https://longbridge.com/en/news/305560069.md)
- [FDA declines approval of Summit Therapeutics' ivonescimab for lung cancer](https://longbridge.com/en/news/305571463.md)
- [Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application](https://longbridge.com/en/news/305571538.md)
- [GE HealthCare Technologies (GEHC) Tests Its Brain Imaging Narrative As Undervalued View Holds](https://longbridge.com/en/news/305561290.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**